👤 Z Zhang

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
145
Articles
214
Name variants
Also published as: A Zhang, AS Zhang, B Zhang, B. Zhang, BZ Zhang, Bingjie Zhang, Bitian Zhang, C Zhang, C-Y Zhang, C. Zhang, C.L. Zhang, CY Zhang, Cheng Zhang, Chenguang Zhang, Chengxiao Zhang, Chenliang Zhang, Chong Zhang, Chunming Zhang, D Zhang, D. R. Zhang, D. Zhang, D.W. Zhang, D.Y. Zhang, D.‐H. Zhang, DD Zhang, DW Zhang, Dandan Zhang, Danyang Zhang, Die Zhang, Dingpeng Zhang, Dingyi Zhang, Donna D Zhang, Donna D. Zhang, E Zhang, F Zhang, F. Zhang, F.W. Zhang, Fan Zhang, Fengqiu Zhang, G Zhang, G. Zhang, Ge Zhang, Guandong Zhang, Guangyong Zhang, Gui-Qiang Zhang, Guofeng Zhang, H Zhang, H. Zhang, H.M. Zhang, H.‐Y. Zhang, HJ Zhang, HL Zhang, HQ Zhang, Hai-Liang Zhang, Hai-Rong Zhang, Hairong Zhang, Han Zhang, Hao Zhang, Haohao Zhang, Heng Zhang, Hong-Jie Zhang, Hongmin Zhang, Hongyong Zhang, Huafeng Zhang, Hui-Wen Zhang, I. Zhang, J Zhang, J. T. Zhang, J. Zhang, J.C. Zhang, J.P. Zhang, J.Y. Zhang, JH Zhang, JJ Zhang, Jianguo Zhang, Jianhua Zhang, Jie Zhang, Jing-Jing Zhang, Jingnan Zhang, Jingyu Zhang, Jinru Zhang, Jinyuan Zhang, Jun Zhang, Junpeng Zhang, K Zhang, K. Zhang, KR Zhang, Kenneth Yin Zhang, L Zhang, L. Zhang, LL Zhang, LY Zhang, Lei Zhang, Li Zhang, Liang-Liang Zhang, Ling-Ling Zhang, Liyan Zhang, Long Zhang, M Zhang, M. Zhang, MB Zhang, MQ Zhang, MengQi Zhang, Mingguang Zhang, N Zhang, N. C. Zhang, N. Zhang, Nannan Zhang, P Zhang, P. Zhang, Pingyu Zhang, Q Zhang, Q. Zhang, Q.H. Zhang, Q.Y. Zhang, Qian Zhang, Qianling Zhang, Qingzhao Zhang, R Zhang, R. N. Zhang, R. Zhang, Rong Zhang, S Zhang, S. Zhang, S.-D. Zhang, S.H. Zhang, S.P. Zhang, S.R. Zhang, SX Zhang, SZ Zhang, Shihua Zhang, Shumiao Zhang, Shuren Zhang, Song-Bai Zhang, Song‐Bai Zhang, T Zhang, T. Zhang, T.P. Zhang, Tianli Zhang, Ting Zhang, V. Zhang, W Zhang, W. Y. Zhang, W. Zhang, W.C. Zhang, WY Zhang, Wei Zhang, Wei-Cheng Zhang, Weibin Zhang, Weijia Zhang, Wen-Yao Zhang, Wendian Zhang, Wenkan Zhang, Wu-Ya Zhang, X Zhang, X. M. Zhang, X. Zhang, X.-X. Zhang, X.X. Zhang, XF Zhang, XJ Zhang, XM Zhang, XQ Zhang, Xiang Zhang, Xianhuan Zhang, Xianpeng Zhang, Xianrui Zhang, Xiaonian Zhang, Xiaoren Zhang, Xiaoxiao Zhang, Xin Zhang, Xinyu Zhang, Xiujuan Zhang, Xuanjun Zhang, Y Zhang, Y. Zhang, Y.D. Zhang, Y.J. Zhang, Y.M. Zhang, Y.Y. Zhang, Y.‐M. Zhang, YF Zhang, YL Zhang, YM Zhang, Ya-Qin Zhang, Yan Zhang, Yan-Xia Zhang, Yangli Zhang, Yanming Zhang, Yanyang Zhang, Yao Zhang, Yaping Zhang, Yi Zhang, Yiguo Zhang, Ying Zhang, Yiwen Zhang, Yu Zhang, Yuan-Yuan Zhang, Yujie Zhang, Yun-Liang Zhang, Z-B Zhang, Z. Zhang, Z.C. Zhang, Z.Q. Zhang, Z.‐X. Zhang, ZP Zhang, ZY Zhang, Zhao Zhang, Zheng Zhang, Zhengwen Zhang, Zhenwei Zhang, Zhihong Zhang, Zijin Zhang
articles
Jie Liu, Jinyuan Zhang, Qianghui Zheng +1 more · 2026 · Inorganic Chemistry · ACS Publications · added 2026-04-20
Glutathione (GSH), the most abundant intracellular thiol-containing antioxidant, plays a pivotal role in cellular metabolism and redox homeostasis. Its critical involvement in cancer and neurodegenera Show more
Glutathione (GSH), the most abundant intracellular thiol-containing antioxidant, plays a pivotal role in cellular metabolism and redox homeostasis. Its critical involvement in cancer and neurodegenerative diseases has made it an important target for thiol detection systems. In this work, we report the design and synthesis of two novel near-infrared (NIR) phosphorescent Ir(III) complexes as multifunctional probes for GSH detection and photodynamic therapy (PDT). These probes feature an α,β-unsaturated ketone moiety that selectively reacts with the thiol group in GSH, enabling the specific sensing of intracellular and extracellular GSH with applications in bioimaging. Beyond their sensing capabilities, both Ir(III) complexes exhibit strong reactive oxygen species (ROS) generation efficiency, aggregation-induced emission (AIE) characteristics, and mitochondria-targeting properties, making them highly effective for PDT. Notably, upon cellular uptake, these complexes deplete mitochondrial GSH, disrupting redox homeostasis and triggering a rapid accumulation of localized ROS. This dual mechanism─combining GSH depletion and enhanced ROS production─induces potent apoptotic cell death. This work provides a strategic approach for developing advanced NIR photosensitizers with AIE activity, mitochondria-specific targeting, and the ability to simultaneously engage type I and type II PDT pathways while modulating intracellular antioxidant defense systems. Such multifunctional theranostic probes offer considerable potential for enhancing the efficacy of photodynamic cancer therapy, particularly in the treatment of hypoxic tumors. Show less
no PDF DOI: 10.1021/acs.inorgchem.5c05682 📎 SI
Ir imaging mitochondria photoactivated
Zichen Xu, Heng Zhang, Shaohua Gou · 2026 · Inorganic Chemistry · ACS Publications · added 2026-04-20
By applying our pioneering "Targeted Drug Conjugate (TDC)" concept, a new PARP1-specific Pt(II)-based TDC for the treatment of ovarian cancer was reported. In vitro biological assays indicated Show more
By applying our pioneering "Targeted Drug Conjugate (TDC)" concept, a new PARP1-specific Pt(II)-based TDC for the treatment of ovarian cancer was reported. In vitro biological assays indicated that the representative compound Ola-604 could target PARP1, exhibit an inhibitory effect on SKOV3 cancer cells, and overcome cisplatin resistance via inducing cell apoptosis, causing cell cycle arrest, enhancing the cellular accumulation of platinum element, promoting the level of DNA platination within the genome, and suppressing DNA damage repair. Notably, compound Ola-604 demonstrated higher tumor growth inhibitory efficacy than cisplatin, olaparib, and their physical mixture in SKOV3 mice xenograft models, while exhibiting lower toxicity. Overall, the TDC entity sets a new benchmark for precision therapy in ovarian cancer. Show less
no PDF DOI: 10.1021/acs.inorgchem.6c00964
DNA-binding Pt
Ke Ren, Lihua Pang, Songyu Lv +7 more · 2026 · ACS Nano Medicine · ACS Publications · added 2026-04-20
no PDF DOI: 10.1021/acsnanomed.5c00021
Yongrui Hai, Ruizhuo Lin, Weike Liao +8 more · 2025 · Molecular Biomedicine · BioMed Central · added 2026-04-20
Abstract Cancer cells rely heavily on de novo pyrimidine synthesis. Inhibiting pyrimidine metabolism directly suppresses tumor growth and fosters immune activation within the tumor microenvironment. D Show more
Abstract Cancer cells rely heavily on de novo pyrimidine synthesis. Inhibiting pyrimidine metabolism directly suppresses tumor growth and fosters immune activation within the tumor microenvironment. Dihydroorotate dehydrogenase (DHODH) is a key enzyme in the de novo pyrimidine synthesis pathway. Inhibiting DHODH can reverse immune suppression and trigger a mild innate immune response. However, the impact of DHODH inhibition on natural killer (NK) cells remains to be explored. In this study, we found that DHODH inhibition promoted NK cell infiltration into tumors efficiently. Mechanistically, DHODH suppression induced mitochondrial oxidative stress, leading to mitochondrial DNA (mtDNA) release into the cytoplasm through voltage-dependent anion channel (VDAC) oligomerization and caspase-3 activation. This subsequently activated the stimulator of interferon gene (STING) pathway, triggered ferroptosis, and induced gasdermin E (GSDME) mediated pyroptosis in cancer cells. These changes collectively facilitated NK cell recruitment. Furthermore, infiltrated NK cells enhanced GSDME-dependent pyroptosis in tumor cells through granzyme release, establishing a positive feedback loop that amplified anti-tumor immunity. Additionally, we developed EA6, a novel DHODH inhibitor that is more effective at promoting NK cell infiltration. In summary, this study reveals that targeting pyrimidine metabolism activates a novel mechanism involving pyroptosis-ferroptosis crosstalk and STING pathway activation to enhance NK cell-mediated immunity. These finding opens new avenues for enhancing the efficacy of targeted nucleotide metabolism in cancer therapy. Show less
📄 PDF DOI: 10.1186/s43556-025-00339-7
Fe ROS mitochondria synthesis
Jiashuo Zheng, Weijia Zhang, Junya Ito +4 more · 2025 · Cell chemical biology · Elsevier · added 2026-04-20
N-acetyl-l-cysteine (NAC) is a medication and a widely used antioxidant in cell death research. Despite its somewhat obscure mechanism of action, its role in inhibiting ferroptosis is gaining increasi Show more
N-acetyl-l-cysteine (NAC) is a medication and a widely used antioxidant in cell death research. Despite its somewhat obscure mechanism of action, its role in inhibiting ferroptosis is gaining increasing recognition. In this study, we demonstrate that NAC treatment rapidly replenishes the intracellular cysteine pool, reinforcing its function as a prodrug for cysteine. Interestingly, its enantiomer, N-acetyl-d-cysteine (d-NAC), which cannot be converted into cysteine, also exhibits a strong anti-ferroptotic effect. We further clarify that NAC, d-NAC, and cysteine all act as direct reducing substrates for GPX4, counteracting lipid peroxidation. Consequently, only GPX4-rather than system xc-, glutathione biosynthesis, or ferroptosis suppressor protein 1-is necessary for NAC and d-NAC to prevent ferroptosis. Additionally, we identify a broad range of reducing substrates for GPX4 in vitro, including β-mercaptoethanol. These findings provide new insights into the mechanisms underlying the protective effects of NAC and other potential GPX4-reducing substrates against ferroptosis. Show less
no PDF DOI: 10.1016/j.chembiol.2025.04.002
Fe amino-acid prodrug
Hui Liu, Mengmeng Pan, Yumeng Li +5 more · 2025 · Journal of translational medicine · BioMed Central · added 2026-04-20
Mitochondria are bilayer membrane organelles with basic metabolic activity. They are considered hubs for biosynthesis, bioenergy, and signaling functions, coordinating major biological pathways. Mitoc Show more
Mitochondria are bilayer membrane organelles with basic metabolic activity. They are considered hubs for biosynthesis, bioenergy, and signaling functions, coordinating major biological pathways. Mitochondria are coupled to the oxidation of fatty acids and pyruvate through electron transport chains and have historically been considered the primary source of cellular energy. Recent studies have depicted that mitochondria are centers that promote inflammatory responses and play a crucial role in combating pathogenic infections. Moreover, mitochondria provide the basis for tumor synthesis metabolism, control redox and calcium homeostasis, participate in transcriptional regulation, and control cell death. Mitochondria are involved in all steps of tumorigenesis. This review discusses the relationship between mitochondria (including mitochondrial metabolism and mitophagy) and tumors, and the relationship between mtDNA and inflammation, as well as its clinical application in inflammatory diseases. More importantly, the application and targeted treatment strategies provide more opportunities for the development of new anticancer drugs. Show less
📄 PDF DOI: 10.1186/s12967-025-06722-w
anticancer mitochondria review synthesis
Yiguo Zhang, Xi Chen, Meng Wang +6 more · 2025 · Cell stress · added 2026-04-20
Differential and even opposing functions of two major antioxidant transcription factors Nrf1 and Nrf2 (encoded by Nfe2l1 and Nfe2l2, respectively) are determined by distinctions in their tempospatial Show more
Differential and even opposing functions of two major antioxidant transcription factors Nrf1 and Nrf2 (encoded by Nfe2l1 and Nfe2l2, respectively) are determined by distinctions in their tempospatial positioning, topological repartitioning, proteolytic processing, and biochemical modification, as well as in their shared evolutionary origin. As a matter of fact, the allelopathic potentials of Nrf1 and Nrf2 (both resembling two entangled 'Yin-Yang' quanta that comply with a dialectic law of the unity of opposites) are fulfilled to coordinately control redox physiological homeostasis so as to be maintained within the presetting thresholds. By putative exponential curves of redox stress and intrinsic anti-redox capability, there is inferable to exist a set point at approaching zero with the 'Golden Mean' for the healthy survival (i.e., dubbed the 'zero theory'). A bulk of the hitherto accumulating evidence demonstrates that the set point of redox homeostasis is dictated selectively by multi-hierarchical threshold settings, in which the living fossil-like Nrf1 acts as a robust indispensable determinon, whereas Nrf2 serves as a versatile chameleon-like master regulon, in governing the redox homeodynamic ranges. This is attributable to the facts that Nrf2 has exerted certain 'double-edged sword' effects on life process, whereas Nrf1 executes its essential physiobiological functions, along with unique pathophysiological phenotypes, by integrating its 'three-in-one' roles elicited as a specific triplet of direct sensor, transducer and effector within multi-hierarchical stress responsive signaling to redox metabolism and target gene reprogramming. Here, we also critically reviewed redox regulation of physio-pathological functions from the eco-evo-devo perspectives, through those coding rules (redox code, stress-coping code, and topogenetic code). The evolving concepts on stress and redox stress were also further revisited by scientific principles of physics and chemistry. Besides, several novel concepts such as oncoprotists, Reverse Central Dogma, and Grand Redox-Unifying Theory' (GRUT) of life, together with diffusive reactive species (DRS)-based murburn concept integrating all stochastic electron-, proton- and/or moiety-transfer reactive and interactive processes (e.g., PCHEMS), are introduced in this interdisciplinary and synthetic review. Show less
📄 PDF DOI: 10.15698/cst2025.07.306
review sensor
Yuexuan Pan, Tetsuro Matsunaga, Tianli Zhang +1 more · 2025 · Biomolecules · MDPI · added 2026-04-20
Oxidation-reduction (redox) reactions are fundamental to sustaining life, with reactive oxygen and nitrogen species playing pivotal roles in cellular signaling and homeostasis. However, excessive oxid Show more
Oxidation-reduction (redox) reactions are fundamental to sustaining life, with reactive oxygen and nitrogen species playing pivotal roles in cellular signaling and homeostasis. However, excessive oxidative stress disrupts redox balance, contributing to a wide range of diseases, including inflammatory and pulmonary disorders, neurodegeneration, and cancer. Although numerous antioxidant therapies have been developed and tested for oxidative stress-related diseases, their clinical efficacy remains limited. Here, we introduce the emerging concept of 'supersulfides', a class of redox molecule species with unique antioxidant and nucleophilic properties, which have recently been recognized as crucial regulators of cellular redox homeostasis. Unlike traditional antioxidants, supersulfides offer novel mechanisms of action that directly target the underlying processes of oxidative stress. This review summarizes current knowledge on supersulfides, highlighting their roles in oxidative stress and associated diseases, as well as the mechanisms underlying oxidative stress-related pathology. The therapeutic potential of synthetic supersulfides for treating oxidative stress-related diseases is also discussed. A comprehensive understanding of the molecular and cellular basis of redox biology can help to guide the development of innovative redox-based therapeutic strategies aimed at preventing and treating diseases associated with disturbed redox regulation. Show less
no PDF DOI: 10.3390/biom15020172
ROS review
Bitian Zhang, Zhang, Bitian, Ping-Chung Leung +7 more · 2025 · BioMed Central · BioMed Central · added 2026-04-20
Lung cancer remains the leading cause of cancer-related mortality globally, necessitating the continual exploration of novel therapeutic targets. The phosphoinositide 3-kinase (PI3K) signaling pathway Show more
Lung cancer remains the leading cause of cancer-related mortality globally, necessitating the continual exploration of novel therapeutic targets. The phosphoinositide 3-kinase (PI3K) signaling pathway plays a pivotal role in oncogenic processes, including cell growth, survival, metabolism and immune modulation. This comprehensive review delineates the distinct roles of PI3K subtypes—PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ—in lung cancer pathogenesis and progression. We evaluate the current landscape of PI3K inhibitors, transitioning from non-selective early-generation compounds to isoform-specific agents, highlighting their clinical efficacy, resistance mechanisms and potential combination strategies. Furthermore, the intricate interplay between PI3K signaling and the tumor immune microenvironment is explored, elucidating how PI3K modulation can enhance immunotherapeutic responses. Metabolic reprogramming driven by PI3K signaling is also dissected, revealing vulnerabilities that can be therapeutically exploited. Despite promising advancements, challenges such as therapeutic resistance and adverse effects underscore the need for personalized medicine approaches and the development of next-generation inhibitors. This review underscores the multifaceted role of PI3K in lung cancer and advocates for integrated strategies to harness its full therapeutic potential, paving the way for improved patient outcomes. Show less
📄 PDF DOI: 10.1186/s12967-025-06144-8
review
MdS VERZA, P Soni, GR Duddukuri +646 more · 2025 · Oncology Research · added 2026-04-20
MdS VERZA, P Soni, GR Duddukuri, F Bray, M Laversanne, H Sung, J Ferlay, RL Siegel, I Soerjomataram, R Malhotra, N Manoharan, SS Deo, S Bhatnagar, JE Carroll, JE Bower, PA Ganz, B Li, H Ming, S Qin, EC Nice, J Dong, Z Du, C Swanton, E Bernard, C Abbosh, F André, J Auwerx, A Balmain, LCP Dharshini, RR Rasmi, C Kathirvelan, KM Kumar, KM Saradhadevi, KM Sakthivel, K Li, Z Deng, C Lei, X Ding, J Li, C Wang, M Neganova, J Liu, Y Aleksandrova, S Klochkov, R Fan, Y Ren, R Wang, S Weng, H Xu, Y Zhang, S Chen, FU Vaidya, A Sufiyan Chhipa, V Mishra, VK Gupta, SG Rawat, A Kumar, M Cai, XL Song, XA Li, M Chen, J Guo, DH Yang, D Dima, D Jiang, DJ Singh, M Hasipek, HS Shah, F Ullah, ET Bin, A Shahriar, AR Mahmud, T Rahman, MH Abir, MFR Siddiquee, S Milewska, K Niemirowicz-Laskowska, G Siemiaszko, P Nowicki, AZ Wilczewska, H Car, WMC van den Boogaard, DSJ Komninos, WP Vermeij, J Moon, I Kitty, K Renata, F Zhao, W Kim, N Chatterjee, GC Walker, R Huang, PK Zhou, FJ Groelly, M Fawkes, RA Dagg, AN Blackford, M Tarsounas, CJ Lord, A Ashworth, ZE Karanjawala, U Grawunder, CL Hsieh, MR Lieber, E Ryan, R Hollingworth, R Grand, US Srinivas, BWQ Tan, BA Vellayappan, AD Jeyasekharan, Y Baiken, D Kanayeva, S Taipakova, R Groisman, AA Ishchenko, D Begimbetova, L Sarmini, M Meabed, E Emmanouil, G Atsaves, E Robeska, BT Karwowski, S Neri, S Guidotti, C Bini, S Pelotti, S D’Adamo, M Minguzzi, T Murmann-Konda, A Soni, M Stuschke, G Iliakis, H Sies, VV Belousov, NS Chandel, MJ Davies, DP Jones, GE Mann, Y Wang, F Li, L Mao, Y Liu, AE Vendrov, MD Stevenson, A Lozhkin, T Hayami, NA Holland, X Yang, MT Keeney, EM Rocha, EK Hoffman, K Farmer, R Di Maio, J Weir, K Wu, AE El Zowalaty, VI Sayin, T Papagiannakopoulos, B Zhang, C Pan, C Feng, C Yan, Y Yu, Z Chen, JYS Lim, JQ Eu, AKMH Chan, BC Goh, L Wang, V Purohit, DM Simeone, CA Lyssiotis, MJ Iqbal, A Kabeer, Z Abbas, HA Siddiqui, D Calina, J Sharifi-Rad, V Shah, HY Lam, CHM Leong, R Sakaizawa, JS Shah, AP Kumar, X An, W Yu, D Tang, L Yang, X Chen, L Sun, N Ouyang, S Shafi, R Zhao, J Pan, L Hong, J Xie, Z Lai, X Zheng, H Liao, Y Xian, Q Li, JN Rana, S Mumtaz, EH Choi, I Han, D Averill-Bates, A Mohsin, K Haneef, A Ilyas, S Zarina, Z Hashim, N Sadeghi, G Boissonneault, M Tavalaee, MH Nasr-Esfahani, M Labrie, JS Brugge, GB Mills, IK Zervantonakis, C Glorieux, S Liu, D Trachootham, P Huang, B Farhood, M Najafi, E Salehi, N Hashemi Goradel, MS Nashtaei, N Khanlarkhani, KF Zahra, R Lefter, A Ali, EC Abdellah, C Trus, A Ciobica, M Wang, M Chang, C Li, Q Chen, Z Hou, B Xing, A O’Reilly, W Zhao, S Wickström, ESJ Arnér, R Kiessling, S Murakami, Y Kusano, K Okazaki, T Akaike, H Motohashi, F Chen, M Xiao, S Hu, MT Bayo Jimenez, K Frenis, O Hahad, S Steven, G Cohen, A Cuadrado, A Namani, Y Li, XJ Wang, X Tang, T Sengoku, M Shiina, K Suzuki, K Hamada, K Sato, A Uchiyama, M McMahon, N Thomas, K Itoh, M Yamamoto, JD Hayes, W Tian, M Rojo de la Vega, CJ Schmidlin, A Ooi, DD Zhang, Y Katoh, K Iida, MI Kang, A Kobayashi, M Mizukami, KI Tong, S Fourquet, R Guerois, D Biard, MB Toledano, A Raghunath, K Sundarraj, R Nagarajan, F Arfuso, J Bian, JW Kaspar, SK Niture, AK Jaiswal, MY Song, DY Lee, KS Chun, EH Kim, L Liang, M Matsumoto, K Iwata, A Umemura, F He, S Adinolfi, T Patinen, A Jawahar Deen, S Pitkänen, J Härkönen, E Kansanen, N Wakabayashi, T Ishii, K Igarashi, JD Engel, SC Lo, X Li, MT Henzl, LJ Beamer, M Hannink, YS Keum, B Choi, P Canning, FJ Sorrell, AN Bullock, T Clifford, JP Acton, SP Cocksedge, KAB Davies, SJ Bailey, M Thiruvengadam, B Venkidasamy, U Subramanian, R Samynathan, M Ali Shariati, M Rebezov, M Ruwali, R Shukla, M Hayashi, T Papgiannakopoulos, H Robertson, AT Dinkova-Kostova, K Taguchi, SB Lee, BN Sellers, GM DeNicola, YC Tang, YJ Chuang, HH Chang, SH Juang, GC Yen, JY Chang, S Kalthoff, U Ehmer, N Freiberg, MP Manns, CP Strassburg, JF Lin, ZX Liu, DL Chen, RZ Huang, F Cao, K Yu, Z Zhu, S Du, Y Du, J Ren, G Ying, Z Yan, C Biswas, N Shah, M Muthu, P La, AP Fernando, S Sengupta, FJ Lei, JY Chiang, HJ Chang, DC Chen, HL Wang, HA Yang, TW Kensler, L Baird, S Dayalan Naidu, TH Rushmore, MR Morton, CB Pickett, R Venugopal, P Nioi, T Chiba, S Takahashi, JL Xiao, HY Liu, CC Sun, CF Tang, W Tu, H Wang, S Li, Q Liu, H Sha, P Stenvinkel, CJ Meyer, GA Block, GM Chertow, PG Shiels, AV Ulasov, AA Rosenkranz, GP Georgiev, AS Sobolev, A Uruno, X Luo, X Zhu, Y Chen, B Xu, X Bai, DJ Schaer, N Schulthess-Lutz, L Baselgia, K Hansen, RM Buzzi, R Humar, X Wang, S Su, Y Zhu, X Cheng, C Cheng, L Chen, FV Reinema, FCGJ Sweep, GJ Adema, WJM Peeters, JWM Martens, J Bussink, D Karagiannis, W Wu, A Li, M Yip, C Gur, FM Kandemir, C Caglayan, E Satıcı, D Sapochnik, AR Raimondi, V Medina, J Naipauer, EA Mesri, O Coso, Y Pu, Y Tan, C Zang, C Cai, L Kong, HH Chen, JY Yao, YT Chen, A Sharma, AK Singh, AA Osman, E Arslan, M Bartels, C Michikawa, A Lindemann, K Tomczak, MA Skowron, G Niegisch, P Albrecht, G van Koeveringe, A Romano, P Albers, H Zhang, J Xu, Y Long, A Maimaitijiang, Z Su, W Li, IC Taritsa, ET Fossel, A Garufi, G Pistritto, V D’Orazi, M Cirone, G D’Orazi, K Lisek, E Campaner, Y Ciani, D Walerych, G Del Sal, A Nazari, P Osati, S Seifollahy Fakhr, F Faghihkhorasani, M Ghanaatian, X Gu, C Mu, R Zheng, Z Zhang, Q Zhang, T Liang, J Wang, J Yang, M Cao, Z Zhao, B Cao, S Yu, D Xue, X Zhou, J Qiu, X Hou, M Huang, J Jin, S Dastghaib, SM Shafiee, F Ramezani, N Ashtari, F Tabasi, J Saffari-Chaleshtori, M Oskomić, A Tomić, L Barbarić, A Matić, DC Kindl, M Matovina, MH Nguyen, NYT Nguyen, YS Chen, HT Nguyen Le, HT Vo, CH Yen, S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, N Azami, L Lin, Q Wu, F Lu, J Lei, Y Zhou, J Krishnaraj, T Yamamoto, R Ohki, G Barrera, MA Cucci, M Grattarola, C Dianzani, G Muzio, S Pizzimenti, L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti, Z Wang, B Yang, Y Xie, Feng S ling, PY Yan, XJ Yao, XX Fan, L Gan, W Wang, J Jiang, K Tian, W Liu, Z Cao, S Karathedath, BM Rajamani, SM Musheer Aalam, A Abraham, S Varatharajan, P Krishnamurthy, C Monge, A Roetto, E Caputo, M Sorice, E Profumo, A Capozzi, S Recalchi, G Riitano, B Di Veroli, P Paramasivan, IH Kankia, SP Langdon, YY Deeni, R Srivastava, R Fernández-Ginés, JA Encinar, G Wells, P Wadowski, M Juszczak, K Woźniak, E Crisman, P Duarte, E Dauden, MI Rodríguez-Franco, MG López, D Zhang, KE Aldrich, L Lockwood, AL Odom, KT Liby, R Afjei, N Sadeghipour, SU Kumar, M Pandrala, V Kumar, SV Malhotra, K Gall Trošelj, M Tomljanović, M Jaganjac, T Matijević Glavan, A Čipak Gašparović, L Milković, M Poornashree, H Kumar, R Ajmeer, R Jain, V Jain, F Pouremamali, A Pouremamali, M Dadashpour, N Soozangar, F Jeddi, W Chen, Z Sun, T Jiang, Z Huang, D Fang, M Robert, BK Kennedy, KC Crasta, S Tao, A Lau, MS Joo, SB Shin, EJ Kim, HJ Koo, H Yim, SG Kim, X Liu, N Hu, RJ Mailloux, U Jakob, J Pi, JW Kupiec-Weglinski Show less
Cancer remains a major global health burden, with rising incidence and mortality linked to aging populations and increased exposure to genotoxic agents. Oxidative stress plays a critical role in cance Show more
Cancer remains a major global health burden, with rising incidence and mortality linked to aging populations and increased exposure to genotoxic agents. Oxidative stress plays a critical role in cancer development, progression, and resistance to therapy. The nuclear factor erythroid 2-related factor 2 (NRF2)-Kelch-like ECH-associated protein 1 (KEAP1)-antioxidant response element (ARE) signaling pathway is central to maintaining redox balance by regulating the expression of antioxidant and detoxification genes. Under physiological conditions, this pathway protects cells from oxidative damage, however, sustained activation of NRF2 in cancer, often due to mutations in KEAP1, supports tumor cell survival, drug resistance, and metabolic reprogramming. Recent studies demonstrate that NRF2 enhances glutathione (GSH) synthesis, induces detoxifying enzymes, and upregulates drug efflux transporters, collectively contributing to resistance against chemotherapy and targeted therapies. The inhibition of NRF2 using small molecules or dietary phytochemicals has shown promise in restoring drug sensitivity in preclinical cancer models. This review highlights the dual role of NRF2 in redox regulation and cancer therapy, emphasizing its potential as a therapeutic target. While targeting NRF2 offers a novel approach to overcoming treatment resistance, further research is needed to enhance specificity and facilitate clinical translation. Show less
📄 PDF DOI: 10.32604/or.2025.065755
ROS amino-acid anticancer review synthesis
Sadeem Qdaisat, Brandon Wummer, Brian D Stover +38 more · 2025 · Nature biomedical engineering · Nature · added 2026-04-20
The success of cancer immunotherapies is predicated on the targeting of highly expressed neoepitopes, which preferentially favours malignancies with high mutational burden. Here we show that early res Show more
The success of cancer immunotherapies is predicated on the targeting of highly expressed neoepitopes, which preferentially favours malignancies with high mutational burden. Here we show that early responses by type-I interferons mediate the success of immune checkpoint inhibitors as well as epitope spreading in poorly immunogenic tumours and that these interferon responses can be enhanced via systemic administration of lipid particles loaded with RNA coding for tumour-unspecific antigens. In mice, the immune responses of tumours sensitive to checkpoint inhibitors were transferable to resistant tumours and resulted in heightened immunity with antigenic spreading that protected the animals from tumour rechallenge. Our findings show that the resistance of tumours to immunotherapy is dictated by the absence of a damage response, which can be restored by boosting early type-I interferon responses to enable epitope spreading and self-amplifying responses in treatment-refractory tumours. Show less
no PDF DOI: 10.1038/s41551-025-01380-1
immunogenic
Yifei Lu, Xiujuan Zhang, Minmin Song +5 more · 2025 · RSC Advances · Royal Society of Chemistry · added 2026-04-20
In this work, three iridium(III) tetrazolato complexes have been used in antibacterial, biofilm removal and for other bioactivities for the first time. Notably, these iridium(III) tetrazolato complexe Show more
In this work, three iridium(III) tetrazolato complexes have been used in antibacterial, biofilm removal and for other bioactivities for the first time. Notably, these iridium(III) tetrazolato complexes with high antibacterial, especially, Ir-CF3TAZ showed the best antimicrobial activity and the most effective hemolytic performance, which may pave the way to explore the value of the complexes for clinical applications in the future. Show less
📄 PDF DOI: 10.1039/D4RA08525F
Ir antibacterial tetrazole
L. Volpicella, G. Punzi, V. Porcelli +494 more · 2025 · Biomolecules · MDPI · added 2026-04-20
L. Volpicella, G. Punzi, V. Porcelli, N. Gambacorta, L. Trisolini, C.L. Pierri, A. De Grassi, D.M. Muoio, R.C. Noland, J.P. Kovalik, S.E. Seiler, M.N. Davies, K.L. Debalsi, O.R. Ilkayeva, R.D. Stevens, I. Kheterpal, J. Zhang, J. Hsu, N. Fatuzzo, N. Weng, W. Michno, W. Dong, M. Kienle, Y. Dai, A. Pasca, M. Abu-Remaileh, N. Rasgon, R.R. Ramsay, R.D. Gandour, F.R. van der Leij, M.A.K. Westin, M.C. Hunt, S.E.H. Alexson, O.J. Martin, D.H. Slentz, J. An, C.B. Newgard, T.R. Koves, K.H. Fisher-Wellman, C.-T. Lin, T.E. Ryan, L.R. Reese, L.A.A. Gilliam, B.L. Cathey, D.S. Lark, C.D. Smith, P.D. Neufer, J.R. Gooding, K.E. Wong, A.H. Wittmann, L. Lindeboom, L. Kjalarsdottir, J.W. Thompson, L.G. Dubois, M.J. Brosnan, T.P. Rolph, P.A. Grimsrud, V. Mezhnina, R. Pearce, A. Poe, N. Velingkaar, A. Astafev, O.P. Ebeigbe, K. Makwana, Y. Sandlers, R.V. Kondratov, M.A.B. Melone, A. Valentino, S. Margarucci, U. Galderisi, A. Giordano, G. Peluso, N.D. Amoedo, S. Sarlak, E. Obre, P. Esteves, H. Bégueret, Y. Kieffer, B. Rousseau, A. Dupis, J. Izotte, N. Bellance, N. Giangregorio, A. Tonazzi, G. Incampo, V. Tragni, C. Indiveri, G. Fiermonte, E. Paradies, S. Todisco, C.M.T. Marobbio, F. Palmieri, T. Haitina, J. Lindblom, T. Renström, R. Fredriksson, A. Vozza, F. De Leonardis, G. Parisi, F.M. Lasorsa, L. Muto, L. Capobianco, G. Agrimi, A. Russo, P. Scarcia, V.A. Zammit, G. Jogl, L. Tong, A.C. Rufer, R. Thoma, M. Hennig, Y.S. Hsiao, I. Lasheras-Otero, I. Feliu, A. Maillo, H. Moreno, M. Redondo-Muñoz, P. Aldaz, A. Bocanegra, A. Olias-Arjona, F. Lecanda, J. Fernandez-Irigoyen, B. Musio, V. Pesce, M.M. Cavalluzzi, G. Petrosillo, G. La Piana, M.N. Sgobba, N. Schlosserová, L. Cafferati Beltrame, R. Di Lorenzo, G. Primiano, A. Tummolo, G. Paterno, R. Gorgoglione, M. Volpicella, V. Iacobazzi, V. Infantino, P. Convertini, L. Console, C. Lanave, C. Saccone, S.M. Houten, R.J.A. Wanders, D. Lacombe, R. Rossignol, C. Caggese, D. D’Elia, G. Pesole, M. Montaruli, L. Laera, F. Colella, V. Scaglione, S. Barile, A.L. Francavilla, D.I. De Luca, X. Wang, C. Yang, C. Huang, W. Wang, G. Chen, B. Bao, Y. Cheng, M. Tian, J. Song, L. Zheng, Q. Tong, R. Vishwa, B. BharathwajChetty, S. Girisa, B.S. Aswani, M.S. Alqahtani, M. Abbas, M. Hegde, A.B. Kunnumakkara, L.T.M. Le, J.R. Thompson, P.X. Dang, J. Bhandari, A. Alam, K. Zacharowski, B. Blackburn, C. Thiemermann, R. Shi, Y. Zhang, Y. Shi, S. Shi, L. Jiang, K. Jaudzems, J. Kuka, A. Gutsaits, K. Zinovjevs, I. Kalvinsh, E. Liepinsh, M. Dambrova, M. Tsoko, F. Beauseigneur, J. Gresti, I. Niot, J. Demarquoy, J. Boichot, J. Bezard, L. Rochette, P. Clouet, M. Kuwajima, H. Harashima, M. Hayashi, S. Ise, M. Sei, K.-m. Lu, H. Kiwada, Y. Sugiyama, K. Shima, D.L. Jenkins, O.W. Griffith, L.T. Izzo, S. Trefely, C. Demetriadou, J.M. Drummond, T. Mizukami, N. Kuprasertkul, A.T. Farria, P.T.T. Nguyen, N. Murali, L. Reich, H. Mao, A. Angelini, S. Li, G. Wang, L. Li, C. Patterson, X. Pi, L. Xie, A.G. Cordente, E. López-Viñas, M.I. Vázquez, P. Gómez-Puertas, G. Asins, D. Serra, F.G. Hegardt, L. Govindasamy, T. Kukar, W. Lian, B. Pedersen, Y. Gu, M. Agbandje-McKenna, S. Jin, R. McKenna, D. Wu, A.R. Kim, R.J. Rylett, B.H. Shilton, Y. Cai, C.N. Cronin, A.G. Engel, K. Ohno, L.B. Hersh, D.W. Rodgers, J.D. McGarry, N.F. Brown, A. Mattevi, A.M. Waterhouse, J.B. Procter, D.M.A. Martin, M. Clamp, G.J. Barton, M.A. Larkin, G. Blackshields, N.P. Brown, R. Chenna, P.A. McGettigan, H. McWilliam, F. Valentin, I.M. Wallace, A. Wilm, R. Lopez, J.F. Chase, S. Violante, L. Ijlst, J. Ruiter, J. Koster, H. van Lenthe, M. Duran, I.T. de Almeida, F.V. Ventura, P.K. Tubbs, M. Morillas, B. Rubí, J. Clotet, J. Ariño, A. Valencia, K. Kashfi, R.L. Mynatt, E.A. Park, G.A. Cook, R.J. Wanders, W.L. Delano, S. Bromberg, A.C. Wallace, R.A. Laskowski, J.M. Thornton, T.R. Altamimi, P.D. Thomas, A.M. Darwesh, N. Fillmore, M.U. Mahmoud, L. Zhang, A. Gupta, R. Al Batran, J.M. Seubert, G.D. Lopaschuk, M.A. Schroeder, H.J. Atherton, M.S. Dodd, P. Lee, L.E. Cochlin, G.K. Radda, K. Clarke, D.J. Tyler, A. Pop, M. Williams, E.A. Struys, M. Monné, E.E.W. Jansen, W.A. Kanhai, M.R.F. Ojeda, A. Tessa, C. Dionisi-Vici, M.R. Baumgartner, Y.H. Chien, C. Loguercio, H.O. De Baulny, M.-C. Nassogne, M. Schiff, R. Wibom, V. Töhönen, M. Barbaro, F.H. Sterky, T. Kucinski, K. Naess, M. Jonsson, S. Edvardson, C. Jalas, D. Soiferman, Y. Kellner, A. Shaag, S.H. Korman, N.D. Fraenkel, M. Ruggiu, M.F. Hossain, A. Menga, A. Castegna, F. Invernizzi, S. Baratta, R. Pons, W. Chung, B. Garavaglia, A. Ribes, R. Parini, M.D. Huertas, M.A. Shahroor, I. Dweikat, M.A. Di Noia, M. Gur, G. Agostino, T. Rinaldi, G. Gasparre, A. Onofrio, G. Redavid, A. Santarsiero, N.C. Williams, D. Iacobazzi, G. De Stefano, L.A.J. O’Neill, X. Li, F. Zhao, Z. Zhao, X. Zhao, H. Meng, D. Zhang, S. Zhao, M. Ding, C. Amat di San Filippo, M.R.G. Taylor, L. Mestroni, L.D. Botto, N. Longo, K. Gotvaldová, J. Špačková, K. Smolková, G. Benard, F. Furt, H. Begueret, E. Passerieux, J.P. Delage, J.M. Baste, P. Moreau, J. Novotný, K. Baslarová, P. Ježek, L. Rossmeislová, J. Gojda, E.M. Palmieri, R. Holewinski, C.L. McGinity, N. Maio, J.M. Weiss, K.M. Miranda, T.A. Rouault, T. Andresson, S. Sharma, X. Sun, S. Agarwal, R. Rafikov, S. Dasarathy, S. Kumar, S.M. Black, J.M. Rutkowsky, T.A. Knotts, K.D. Ono-Moore, C.S. McCoin, S. Huang, D. Schneider, S. Singh, S.H. Adams, D.H. Hwang, L. Amadori, C. Calcagno, D.M. Fernandez, S. Koplev, N. Fernandez, R. Kaur, P. Mury, N.S. Khan, S. Sajja, R. Shamailova, A. Ta-Shma, P. Stepensky, S. Zenvirt, O. Elpeleg, A.J.J.T. Rein, T. Hu, C.H. Liu, M. Lei, Q. Zeng, H. Tang, N. Zhang, C. Garcia, C.J. Andersen, C.N. Blesso, M. Wang, K. Wang, X. Liao, H. Hu, L. Chen, L. Meng, W. Gao, Q. Li, G. Ghilardi, L. Paruzzo, J. Svoboda, E.A. Chong, A.A. Shestov, I.J. Cohen, G. Gabrielli, S.D. Nasta, P. Porazzi, J.B. Baell, J.W.M. Nissink, N. Wiedemar, D.A. Hauser, P. Mäser, M. Favia, A. Muscella, L. Guerra, C. Jose, T. Zhao, X. Mu, Q. You, A.D.R. Campos-Contreras, M. Díaz-Muñoz, F.G. Vázquez-Cuevas, L. Nicassio, F. Fracasso, G. Sirago, C. Musicco, A. Picca, E. Marzetti, R. Calvani, P. Cantatore, M.N. Gadaleta, P. Cassano, A.M.S. Lezza, V. Capelli, A.M. Timperio, M. Calvani, L. Mosconi Show less
Carnitine O-acetyltransferase (CRAT) is a key mitochondrial enzyme involved in maintaining metabolic homeostasis by mediating the reversible transfer of acetyl groups between acetyl-CoA and carnitine. Show more
Carnitine O-acetyltransferase (CRAT) is a key mitochondrial enzyme involved in maintaining metabolic homeostasis by mediating the reversible transfer of acetyl groups between acetyl-CoA and carnitine. This enzymatic activity ensures the optimal functioning of mitochondrial carbon flux by preventing acetyl-CoA accumulation, buffering metabolic flexibility, and regulating the balance between fatty acid and glucose oxidation. CRAT’s interplay with the mitochondrial carnitine shuttle, involving carnitine palmitoyltransferases (CPT1 and CPT2) and the carnitine carrier (SLC25A20), underscores its critical role in energy metabolism. Emerging evidence highlights the structural and functional diversity of CRAT and structurally related acetyltransferases across cellular compartments, illustrating their coordinated role in lipid metabolism, amino acid catabolism, and mitochondrial bioenergetics. Moreover, the structural insights into CRAT have paved the way for understanding its regulation and identifying potential modulators with therapeutic applications for diseases such as diabetes, mitochondrial disorders, and cancer. This review examines CRAT’s structural and functional aspects, its relationships with carnitine shuttle members and other carnitine acyltransferases, and its broader role in metabolic health and disease. The potential for targeting CRAT and its associated pathways offers promising avenues for therapeutic interventions aimed at restoring metabolic equilibrium and addressing metabolic dysfunction in disease states. Show less
📄 PDF DOI: 10.3390/biom15020216
amino-acid mitochondria review
H Zhou, J Ferlay, RL Siegel +660 more · 2025 · Oncology Reports · added 2026-04-20
H Zhou, J Ferlay, RL Siegel, M Laversanne, I Soerjomataram, A Jemal, F Bray, PS Steeg, KD Miller, HE Fuchs, FX Xu, YL Zhang, JJ Liu, DD Zhang, HB Chen, K Saxena, MK Jolly, JA Bertout, SA Patel, MC Simon, X Meng, FM Kong, J Yu, A Challapalli, L Carroll, EO Aboagye, DC Hinshaw, LA Shevde, P Desai, N Takahashi, R Kumar, S Nichols, J Malin, A Hunt, C Schultz, Y Cao, D Tillo, D Nousome, FF Tam, KL Ning, M Lee, JM Dumlao, JC Choy, AA Tirpe, D Gulei, SM Ciortea, C Crivii, I Berindan-Neagoe, EB Rankin, AJ Giaccia, GN Masoud, W Li, Y Della Rocca, L Fonticoli, TS Rajan, O Trubiani, S Caputi, F Diomede, J Pizzicannella, GD Marconi, SG Zeng, X Lin, JC Liu, J Zhou, RY Hapke, SM Haake, S Musleh Ud Din, SG Streit, BT Huynh, C Hana, AN Abraham, A Hussein, S Liu, Y Zhan, J Luo, J Feng, J Lu, H Zheng, Q Wen, S Fan, C Wang, S Xu, X Yang, W Luo, H Hu, R Chang, J Zhong, M Knabel, R O'Meally, RN Cole, A Pandey, GL Semenza, Y Wei, D Wang, F Jin, Z Bian, L Li, H Liang, M Li, L Shi, C Pan, D Zhu, X Ji, R Zhu, C Gao, H Xie, X Gong, H Jiang, H Zhao, M Zhang, Y He, X Li, Y Xu, X Liu, S Jiang, R Wang, H Yan, L Jin, X Dou, D Chen, V Becker, X Yuan, AS Boewe, E Ampofo, E Ebert, J Hohneck, RM Bohle, E Meese, Y Zhao, MD Menger, J Zhao, CR Qiao, Z Ding, YL Sheng, XN Li, Y Yang, DY Zhu, CY Zhang, DL Liu, K Wu, S Zhao, C Han, Y Zhang, F Liu, J Ren, HL Yin, HW Xu, QY Lin, RD Leone, JD Powell, Z Yu, J Zou, F Xu, J Jin, G Yu, J Gu, S Yang, X Wang, Y Wu, J Wei, J Xu, AL Jackson, B Zhou, WY Kim, KL Eales, KER Hollinshead, DA Tennant, E Dai, W Wang, Y Li, D Ye, R Courtnay, DC Ngo, N Malik, K Ververis, SM Tortorella, TC Karagiannis, F Luo, N Yan, S Li, G Cao, Q Cheng, Q Xia, H Wang, S Shang, MZ Wang, Z Xing, N He, H Nisar, PM Sanchidrián González, M Brauny, FM Labonté, C Schmitz, MD Roggan, B Konda, CE Hellweg, Z Guo, L Hu, Q Wang, Y Wang, XP Liu, C Chen, W Hu, X Zhang, C Liang, C Wu, S Wan, L Xu, S Wang, J Wang, X Huang, C Zhang, L Zhou, Y Du, C Li, H Ren, L Zheng, PE Porporato, N Filigheddu, JMB Pedro, G Kroemer, L Galluzzi, OT Brustugun, RX Huang, PK Zhou, H Chen, Z Han, Q Luo, Q Li, H Zuo, L Gong, C Liu, S Han, T Zhou, LY Zhang, JZ He, ZM Miao, YY Li, YM Zhang, ZW Liu, SZ Zhang, Y Chen, GC Zhou, YQ Liu, LH Gray, AD Conger, M Ebert, S Hornsey, OC Scott, AB Herrera-Campos, E Zamudio-Martinez, D Delgado-Bellido, M Fernández-Cortés, LM Montuenga, FJ Oliver, A Garcia-Diaz, Q Guo, F Lan, X Yan, Z Xiao, Q Zhang, S Roy, S Kumaravel, A Sharma, CL Duran, KJ Bayless, S Chakraborty, CY Hu, CF Hung, PC Chen, JY Hsu, CT Wang, MD Lai, YS Tsai, AL Shiau, GS Shieh, CL Wu, A Mancino, T Schioppa, P Larghi, F Pasqualini, M Nebuloni, IH Chen, S Sozzani, JM Austyn, A Mantovani, A Sica, X Peng, J Huang, Y Tao, HK Eltzschig, LF Thompson, J Karhausen, RJ Cotta, JC Ibla, SC Robson, SP Colgan, J Li, L Wang, X Chen, Y Ping, L Huang, D Yue, Z Zhang, F Wang, SM An, HM Lei, XP Ding, F Sun, YB Tang, HZ Chen, Y Shen, L Zhu, A Kogita, Y Togashi, H Hayashi, S Sogabe, M Terashima, MA De Velasco, K Sakai, Y Fujita, S Tomida, Y Takeyama, S Karan, MY Cho, H Lee, HS Park, M Sundararajan, JL Sessler, KS Hong, MHY Cheng, Y Mo, G Zheng, LC Clark, R Wolf, D Granger, Z Taylor, X Sun, G Niu, N Chan, B Shen, MV Shirmanova, MM Lukina, MA Sirotkina, LE Shimolina, VV Dudenkova, NI Ignatova, S Tobita, VI Shcheslavskiy, EV Zagaynova, JM Vanderkooi, G Maniara, TJ Green, DF Wilson, CJ Koch, SM Evans, MR Horsman, BS Sørensen, M Busk, DW Siemann, C Huang, J Liang, X Lei, X Xu, L Luo, X Hu, J Gou, W Lin, F Yang, C Liao, D Nasri, R Manwar, A Kaushik, EE Er, K Avanaki, KA Krohn, JM Link, RP Mason, JR Brender, Y Saida, N Devasahayam, MC Krishna, S Kishimoto, I Godet, S Doctorman, F Wu, DM Gilkes, K Matsumoto, JB Mitchell, W Qin, C Xu, C Yu, S Shen, W Huang, DS Vikram, JL Zweier, P Kuppusamy, B Epel, MK Bowman, C Mailer, HJ Halpern, B Hao, H Dong, R Xiong, C Song, N Li, Q Geng, R Zhang, L Lai, J He, D You, W Duan, X Dong, Y Zhu, L Lin, C Ostheimer, M Bache, A Güttler, M Kotzsch, D Vordermark, A Giatromanolaki, AL Harris, AH Banham, CA Contrafouris, MI Koukourakis, H Geng, L Chen, S Lv, SJ Kim, ZN Rabbani, RT Vollmer, EG Schreiber, E Oosterwijk, MW Dewhirst, Z Vujaskovic, MJ Kelley, D Coppola, M Szabo, D Boulware, P Muraca, M Alsarraj, AF Chambers, TJ Yeatman, T Reese, K Stępień, RP Ostrowski, E Matyja, SW Kim, IK Kim, JH Ha, CD Yeo, HH Kang, JW Kim, SH Lee, O Thews, P Vaupel, M Heyboer, D Sharma, W Santiago, N McCulloch, LW Jones, BL Viglianti, JA Tashjian, SM Kothadia, ST Keir, SJ Freedland, MQ Potter, EJ Moon, T Schroeder, JE Herndon, S Jo, J Jeon, G Park, HK Do, J Kang, KJ Ahn, SY Ma, YM Choi, D Kim, B Youn, Y Ki, P Ghosh, C Vidal, S Dey, L Zhang, TM Ashton, WG McKenna, LA Kunz-Schughart, GS Higgins, B Kalyanaraman, G Cheng, M Hardy, M You, M Shameem, AJ Bagherpoor, A Nakhi, P Dosa, G Georg, F Kassie, M Skwarski, DR McGowan, E Belcher, F Di Chiara, D Stavroulias, M McCole, JL Derham, KY Chu, E Teoh, J Chauhan, M Benej, X Hong, S Vibhute, S Scott, J Wu, E Graves, QT Le, AC Koong, B Yu, S Sohoni, T Wang, SP Kalainayakan, PC Konduri, A Ashrafi, P Modareszadeh, N Salamat, PS Alemi, E Berisha, TW Secomb, V Sukhatme, G Bouche, L Meheus, VP Sukhatme, P Pantziarka, BJT Reymen, MW van Gisbergen, AJG Even, CML Zegers, M Das, E Vegt, JE Wildberger, FM Mottaghy, A Yaromina, LJ Dubois, PP Wong, N Bodrug, KM Hodivala-Dilke, S Guelfi, K Hodivala-Dilke, G Bergers, C Wigerup, S Påhlman, D Bexell, Y Xia, HK Choi, K Lee, L Iommarini, AM Porcelli, G Gasparre, I Kurelac, N Albadari, S Deng, J Ma, K Cao, X Ling, P Zhang, J Zhu, H Deng, P Li, Q Hang, Y Jin, M Chen, MS Lara, CM Blakely, JW Riess, H Zhu, S Zhang, W Tian, C Cao, L Shu, A Mahdi, B Darvishi, K Majidzadeh-A, M Salehi, L Farahmand, Z Xie, T Zou, JL Bryant, SL Meredith, KJ Williams, A White, WR Wilson, MP Hay, SX Chen, J Zhang, F Xue, W Liu, Y Kuang, B Gu, S Song, F Shepherd, G Koschel, J Von Pawel, U Gatzmeier, N Van Zandwiyk, P Woll, R Van Klavren, P Krasko, P Desimone, M Nicolson, L Marcu, I Olver, K Graham, E Unger, D Lindsay, CM Garvey, SM Mumenthaler, J Foo, C Meaney, GG Powathil, P Lambin, M Kohandel, BT Oronsky, SJ Knox, JJ Scicinski, B Oronsky, J Scicinski, S Ning, D Peehl, A Oronsky, P Cabrales, M Bednarski, S Knox, L Zhao, C Shen, Y Luo, X Hou, Y Qi, Z Huang, L Gao, M Wu, Y Zhou, X Feng, Z Wu, X Rao, R Zhou, R Meng, P Dey, R Das, S Chatterjee, R Paul, U Ghosh, Y Demizu, O Fujii, H Iwata, N Fuwa, SM Bentzen, V Gregoire, G Meijer, J Steenhuijsen, M Bal, K De Jaeger, D Schuring, J Theuws Show less
Non-small cell lung cancer (NSCLC) is one of the most prevalent and lethal types of cancers worldwide and its high incidence and mortality rates pose a significant public health challenge. Despite sig Show more
Non-small cell lung cancer (NSCLC) is one of the most prevalent and lethal types of cancers worldwide and its high incidence and mortality rates pose a significant public health challenge. Despite significant advances in targeted therapy and immunotherapy, the overall prognosis of patients with NSCLC remains poor. Hypoxia is a critical driving factor in tumor progression, influencing the biological behavior of tumor cells through complex molecular mechanisms. The present review systematically examined the role of the hypoxic microenvironment in NSCLC, demonstrating its crucial role in promoting tumor cell growth, invasion and metastasis. Additionally, it has been previously reported that the hypoxic microenvironment enhances tumor cell resistance by activating hypoxia-inducible factor and regulating exosome secretion. The hypoxic microenvironment also enables tumor cells to adapt to low oxygen and nutrient-deficient conditions by enhancing metabolic reprogramming, such as through upregulating glycolysis. Further studies have shown that the hypoxic microenvironment facilitates immune escape by modulating tumor-associated immune cells and suppressing the antitumor response of the immune system. Moreover, the hypoxic microenvironment increases tumor resistance to radiotherapy, chemotherapy and other types of targeted therapy through various pathways, significantly reducing the therapeutic efficacy of these treatments. Therefore, it could be suggested that early detection of cellular hypoxia and targeted therapy based on hypoxia may offer new therapeutic approaches for patients with NSCLC. The present review not only deepened the current understanding of the mechanisms of action and role of the hypoxic microenvironment in NSCLC but also provided a solid theoretical basis for the future development of precision treatments for patients with NSCLC. Show less
📄 PDF DOI: 10.3892/or.2024.8862
anticancer review
Yifei Pan, Junlin Lei, Shiqi Mou +7 more · 2025 · Journal of the American Chemical Society · ACS Publications · added 2026-04-20
Biomolecular condensates exhibit distinct microenvironments that arise from interactions between proteins, RNA, and solutions. In aqueous solutions, these membraneless structures constantly encounter Show more
Biomolecular condensates exhibit distinct microenvironments that arise from interactions between proteins, RNA, and solutions. In aqueous solutions, these membraneless structures constantly encounter small molecules that could affect the structure and properties of the condensates. However, the effects of organic small molecules in water solutions on the microenvironments of condensates remain poorly understood. In this study, we used various organic solutes as an example to explore how small molecules could influence the physicochemical properties in the microenvironment of protein condensates. Particularly, we quantitatively studied micropolarity and microviscosity using a combination of techniques, including fluorescence lifetime imaging microscopy, fluorescence recovery after photobleaching, and passive rheology. Unexpectedly, our results revealed that the microenvironment was not correlated with the polarity of organic solutes; instead, the correlation was observed on the interaction strength between water and small molecules. We found that solutes with stronger interaction with water and weaker interaction with proteins increase the micropolarity and decrease the microviscosity of condensates. Furthermore, we demonstrated that the modulation of the micropolarity of condensates could impact the miscibility of multicomponent condensates. Finally, we showed that organic solutes could influence the micropolarity of condensates and the partitioning of products in condensates, thus affecting the rate and equilibrium of the chemical reactions. In summary, our work provides a quantitative analysis of how the microenvironment of biomolecular condensates is impacted by organic solutes. Since protein condensates coexist with various types of metabolites in the aqueous cellular milieu, results from this work offer insights into how organic metabolites could regulate the microenvironment and behaviors of biological condensates. Show less
no PDF DOI: 10.1021/jacs.5c04180
biomolecular condensates fluorescence lifetime imaging microscopy fluorescence recovery after photobleaching influence on physicochemical properties microenvironment micropolarity microviscosity modulation of microenvironment
Dongfan Song, Xiaoyu Wang, Zihan Zhao +3 more · 2025 · JACS Au · ACS Publications · added 2026-04-20
Cancer cells often upregulate ribosome biogenesis to meet increased protein synthesis demands for rapid proliferation; therefore, targeting ribosome biogenesis has emerged as a promising cancer therap Show more
Cancer cells often upregulate ribosome biogenesis to meet increased protein synthesis demands for rapid proliferation; therefore, targeting ribosome biogenesis has emerged as a promising cancer therapeutic strategy. Herein, we introduce two Pt complexes, ataluren monosubstituted platinum(IV) (SPA, formula: c,c,t,-[Pt(NH3)2Cl2(OH)(C15H8FN2O3)], where C15H8FN2O3 = ataluren) and ataluren bisubstituted platinum(IV) complex (DPA, formula: c,c,t,-[Pt(NH3)2Cl2(C15H8FN2O3)2], where C15H8FN2O3 = ataluren), which effectively suppress ribosome biogenesis by inhibiting 47s pre-RNA expression. Furthermore, SPA and DPA induce nucleolar stress by dispersing nucleolar protein NPM1, ultimately inhibiting protein generation in tumor cells. More importantly, DPA exhibits superior cytotoxicity to various cancer cells and in vivo antitumor efficacy compared to cisplatin, with lower systemic toxicity. Notably, in clinically relevant models, including orthotopic hepatic tumor-bearing mice and patient-derived bladder cancer organoids, DPA outperforms cisplatin significantly, with the added benefit of oral administration, enhancing clinical feasibility. To our knowledge, DPA emerges as the pioneering Pt(IV) agent targeting the ribosome, providing new insights for designing next-generation metal-based therapeutics. Show less
no PDF DOI: 10.1021/jacsau.4c00652
Au Pt
Dandan Zhang, Mengshan Li, A.F.M. Motiur Rahman +2 more · 2025 · Journal of Molecular Structure · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.molstruc.2024.140044
Biometal
Panpan Wang, Hongbao Fang, Mengmeng Wang +5 more · 2025 · Chinese Chemical Letters · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.cclet.2024.110099
Biometal
Edward C. Lant, Russell J. Needham, Zijin Zhang +5 more · 2025 · ChemCatChem · Wiley · added 2026-05-01
no PDF DOI: 10.1002/cctc.202401863
Biometal
Xin Chen, Andrey S. Tsvetkov, Han-Ming Shen +66 more · 2024 · Autophagy · Taylor & Francis · added 2026-04-20
Macroautophagy/autophagy is a complex degradation process with a dual role in cell death that is influenced by the cell types that are involved and the stressors they are exposed to. Ferroptosis is an Show more
Macroautophagy/autophagy is a complex degradation process with a dual role in cell death that is influenced by the cell types that are involved and the stressors they are exposed to. Ferroptosis is an iron-dependent oxidative form of cell death characterized by unrestricted lipid peroxidation in the context of heterogeneous and plastic mechanisms. Recent studies have shed light on the involvement of specific types of autophagy (e.g. ferritinophagy, lipophagy, and clockophagy) in initiating or executing ferroptotic cell death through the selective degradation of anti-injury proteins or organelles. Conversely, other forms of selective autophagy (e.g. reticulophagy and lysophagy) enhance the cellular defense against ferroptotic damage. Dysregulated autophagy-dependent ferroptosis has implications for a diverse range of pathological conditions. This review aims to present an updated definition of autophagy-dependent ferroptosis, discuss influential substrates and receptors, outline experimental methods, and propose guidelines for interpreting the results.Abbreviation: 3-MA:3-methyladenine; 4HNE: 4-hydroxynonenal; ACD: accidentalcell death; ADF: autophagy-dependentferroptosis; ARE: antioxidant response element; BH2:dihydrobiopterin; BH4: tetrahydrobiopterin; BMDMs: bonemarrow-derived macrophages; CMA: chaperone-mediated autophagy; CQ:chloroquine; DAMPs: danger/damage-associated molecular patterns; EMT,epithelial-mesenchymal transition; EPR: electronparamagnetic resonance; ER, endoplasmic reticulum; FRET: Försterresonance energy transfer; GFP: green fluorescent protein;GSH: glutathione;IF: immunofluorescence; IHC: immunohistochemistry; IOP, intraocularpressure; IRI: ischemia-reperfusion injury; LAA: linoleamide alkyne;MDA: malondialdehyde; PGSK: Phen Green™ SK;RCD: regulatedcell death; PUFAs: polyunsaturated fatty acids; RFP: red fluorescentprotein;ROS: reactive oxygen species; TBA: thiobarbituricacid; TBARS: thiobarbituric acid reactive substances; TEM:transmission electron microscopy. Show less
no PDF DOI: 10.1080/15548627.2024.2319901
Fe
Yi Li, Ben Liu, Yue Zheng +6 more · 2024 · Journal of Medicinal Chemistry · ACS Publications · added 2026-04-20
Title: Photoinduction of Ferroptosis and cGAS-STING Activation by a H Abstract: Triggering ferroptosis represents a promising anticancer therapeutic strategy, but the development of a selective ferro Show more
Title: Photoinduction of Ferroptosis and cGAS-STING Activation by a H Abstract: Triggering ferroptosis represents a promising anticancer therapeutic strategy, but the development of a selective ferroptosis inducer for cancer-specific therapy remains a great challenge. Herein, a H2S-responsive iridium(III) complex NA-Ir has been well-designed as a ferroptosis inducer. NA-Ir could selectively light up H2S-rich cancer cells, primarily localize in mitochondria, intercalate into mitochondrial DNA (mtDNA), and induce mtDNA damage, exhibiting higher anticancer activity under light irradiation. Mechanistic studies showed that NA-Ir-mediated PDT triggered lipid peroxidation and glutathione peroxidase 4 downregulation through ROS production and GSH depletion, resulting in ferroptosis through multiple pathways. Moreover, the intense mtDNA damage can activate the cyclic GMP-AMP synthase-stimulator of the interferon gene (cGAS-STING) pathway, leading to ferritinophagy and further ferroptosis. RNA-sequencing analysis showed that NA-Ir-mediated PDT mainly affects the expression of genes related to ferroptosis, autophagy, and cancer immunity. This study demonstrates the first cancer-specific example with ferroptosis and cGAS-STING activation, which provides a new strategy for multimodal synergistic therapy. Show less
📄 PDF DOI: 10.1021/acs.jmedchem.4c01065
Biometal Fe Ir
Huanping Xie, Borong Su, Hailang Cui +5 more · 2024 · The Journal of Organic Chemistry · ACS Publications · added 2026-04-20
To date, a general approach for the direct α-acyloxylation of cyclic 1,3-dicarbonyls remains challenging. Herein, we report a Pd-catalyzed α-acyloxylation of cyclic 1,3-dicarbonyl-derived hypervalent Show more
To date, a general approach for the direct α-acyloxylation of cyclic 1,3-dicarbonyls remains challenging. Herein, we report a Pd-catalyzed α-acyloxylation of cyclic 1,3-dicarbonyl-derived hypervalent iodine compounds with highly abundant carboxylic acids. Our approach utilizes a commercially available Pd(OAc)2 catalyst, which exhibits mild reaction conditions, scalability, operational simplicity, and robustness against moisture and air. Importantly, our approach eliminates the need for excess carboxylic acids (only 1 equiv) and the use of explosive peroxides and is compatible with diverse complex substrates (e.g., glycyrrhetinic acid and celastrol). The power of this method is further demonstrated through significantly simplifying a previous synthesis. Show less
no PDF DOI: 10.1021/acs.joc.4c02492
Pd
Han Zhang, Fei Xie, Xiao-Ya Yuan +8 more · 2024 · Acta pharmacologica Sinica · Nature · added 2026-04-20
The development of targeted chemotherapeutic agents against colorectal cancer (CRC), one of the most common cancers with a high mortality rate, is in a constant need. Nannocystins are a family of myxo Show more
The development of targeted chemotherapeutic agents against colorectal cancer (CRC), one of the most common cancers with a high mortality rate, is in a constant need. Nannocystins are a family of myxobacterial secondary metabolites featuring a 21-membered depsipeptide ring. The in vitro anti-CRC activity of natural and synthetic nannocystins was well documented, but little is known about their in vivo efficacy and if positive, the underlying mechanism of action. In this study we synthesized a nitroaromatic nannocystin through improved preparation of a key fragment, and characterized its in vitro activity and in vivo efficacy against CRC. We first described the total synthesis of compounds 2-4 featuring Heck macrocyclization to forge their 21-membered macrocycle. In a panel of 7 cancer cell lines from different tissues, compound 4 inhibited the cell viability with IC values of 1-6 nM. In particular, compound 4 (1, 2, 4 nM) inhibited the proliferation of CRC cell lines (HCT8, HCT116 and LoVo) in both concentration and time dependent manners. Furthermore, compound 4 concentration-dependently inhibited the colony formation and migration of CRC cell lines. Moreover, compound 4 induced cell cycle arrest at sub-G1 phase, apoptosis and cellular senescence in CRC cell lines. In three patient-derived CRC organoids, compound 4 inhibited the PDO with IC values of 3.68, 28.93 and 11.81 nM, respectively. In a patient-derived xenograft mouse model, injection of compound 4 (4, 8 mg/kg, i.p.) every other day for 12 times dose-dependently inhibited the tumor growth without significant change in body weight. We conducted RNA-sequencing, molecular docking and cellular thermal shift assay to elucidate the anti-CRC mechanisms of compound 4, and revealed that it exerted its anti-CRC effect at least in part by targeting AKT1. Show less
no PDF DOI: 10.1038/s41401-024-01231-w
anticancer docking synthesis
Wei Gao, Ya-Fang Liu, Yan-Xia Zhang +7 more · 2024 · Cell Death Discovery · Nature · added 2026-04-20
For a long time, hydrogen sulfide (H2S) has been considered a toxic compound, but recent studies have found that H2S is the third gaseous signaling molecule which plays a vital role in physiological a Show more
For a long time, hydrogen sulfide (H2S) has been considered a toxic compound, but recent studies have found that H2S is the third gaseous signaling molecule which plays a vital role in physiological and pathological conditions. Currently, a large number of studies have shown that H2S mediates apoptosis through multiple signaling pathways to participate in cancer occurrence and development, for example, PI3K/Akt/mTOR and MAPK signaling pathways. Therefore, the regulation of the production and metabolism of H2S to mediate the apoptotic process of cancer cells may improve the effectiveness of cancer treatment. In this review, the role and mechanism of H2S in cancer cell apoptosis in mammals are summarized. Show less
📄 PDF DOI: 10.1038/s41420-024-01868-w
review
Haiping Lin, Yang Luo, Tingyue Gong +5 more · 2024 · Cellular oncology (Dordrecht, Netherlands) · Springer · added 2026-04-20
PURPOSE: Growth differentiating Factor 15 (GDF15) is linked to several cancers, but its effect on chemoresistance in colorectal cancer (CRC) remains unclear. Here, we investigated the role of GDF15 in Show more
PURPOSE: Growth differentiating Factor 15 (GDF15) is linked to several cancers, but its effect on chemoresistance in colorectal cancer (CRC) remains unclear. Here, we investigated the role of GDF15 in the chemotherapeutic response of CRC patients to oxaliplatin (L-OHP). METHODS: GDF15 levels in serum and tumour tissues were detected in CRC patients have received L-OHP-based neoadjuvant chemotherapy. The effects of GDF15 neutralization or GDF15 knockdown on cell proliferation, apoptosis and intracellular reactive oxygen species (ROS) levels were analysed in vitro and in vivo. Co-immunoprecipitation (Co-IP), Chromatin Immunoprecipitation (ChIP) and luciferase reporter assays were used to explore the interaction between GDF15 and Nrf2. RESULTS: In this study, we found that GDF15 alleviates oxidative stress to induce chemoresistance of L-OHP in CRC. Mechanically, GDF15 posttranscriptionally regulates protein stability of Nrf2 through the canonical PI3K/AKT/GSK3β signaling pathway, and in turn, Nrf2 acts as a transcription factor to regulate GDF15 expression to form a positive feedback loop, resulting in the maintenance of redox homeostasis balance in CRC. Furthermore, a positive correlation between GDF15 and Nrf2 was observed in clinical CRC samples, and simultaneous overexpression of both GDF15 and Nrf2 was associated with poor prognosis in CRC patients treated with L-OHP. Simultaneous inhibition of both GDF15 and Nrf2 significantly increases the response to L-OHP in an L-OHP-resistant colorectal cancer cells-derived mouse xenograft model. CONCLUSION: This study identified a novel GDF15-Nrf2 positive feedback loop that drives L-OHP resistance and suggested that the GDF15-Nrf2 axis is a potential therapeutic target for the treatment of L-OHP-resistant CRC. Show less
no PDF DOI: 10.1007/s13402-024-00918-w
Co ROS amino-acid
Donna D Zhang · 2024 · Nature cell biology · Nature · added 2026-04-20
Ferroptosis, spurred by excess labile iron and lipid peroxidation, is implicated in various diseases. Advances have been made in comprehending the lipid-peroxidation side of ferroptosis, but the exact Show more
Ferroptosis, spurred by excess labile iron and lipid peroxidation, is implicated in various diseases. Advances have been made in comprehending the lipid-peroxidation side of ferroptosis, but the exact role of iron in driving ferroptosis remains unknown. Although iron overload is characterized in multiple disease states, the potential role of ferroptosis within them remains undefined. This overview focuses on the 'ferro' side of ferroptosis, highlighting iron dysregulation in human diseases and potential therapeutic strategies targeting iron regulation and metabolism. Show less
no PDF DOI: 10.1038/s41556-024-01361-7
Fe review
Guofeng Zhang, Xue Hao, Yongbin Zou +4 more · 2024 · Journal of Materials Chemistry A · Royal Society of Chemistry · added 2026-04-20
Developing a new generation of increased energy, stability, and easily applicable N-rich energetic materials to replace RDX and HMX has posed significant challenges over the past decade. This Show more
Developing a new generation of increased energy, stability, and easily applicable N-rich energetic materials to replace RDX and HMX has posed significant challenges over the past decade. This work presents the design and synthesis of a series of novel N-rich energetic materials (N1 to N3 series) based on the triazole–tetrazole system. Among these, the N3 series demonstrates exceptional detonation performance and stability. It is noteworthy that the N3-3 molecule has achieved the best overall performance among N-rich energetic materials, with an onset decomposition temperature of 302 °C and a detonation velocity of 9341 m s−1, which significantly surpasses that of HMX. Additionally, structural studies of the N1 molecule reveal that the positioning effect of the nitro group and steric hindrance within the molecule disrupt the planar characteristics of the triazole–tetrazole system. In contrast, the amino group in the N3 series enhances molecular planarity, facilitating the formation of large conjugated systems and extensive hydrogen bond networks in N-rich energetic materials. This approach effectively enhances the stability of energetic material molecules and offers valuable insights for the development and design of stable N-rich energetic compounds. Show less
📄 PDF DOI: 10.1039/D4TA06447J
synthesis tetrazole
C. Crivelli, S. Garcia-Madrona, M. Gil-Minguez +428 more · 2024 · Frontiers in Neuroscience · Frontiers · added 2026-04-20
C. Crivelli, S. Garcia-Madrona, M. Gil-Minguez, R. Lujan, A. Almeida, S. Moncada, J. P. Bolanos, C. Angebault, J. Fauconnier, S. Patergnani, J. Rieusset, A. Danese, C. A. Affortit, A. Ardalan, S. Sowlati-Hashjin, H. Oduwoye, S. O. Uwumarenogie, M. Karttunen, M. D. Smith, A. Atlante, G. Amadoro, V. Latina, D. Valenti, M. Belanger, I. Allaman, P. J. Magistretti, K. F. Bell, B. Al-Mubarak, J. H. Fowler, P. S. Baxter, K. Gupta, T. Tsujita, A. M. Bertholet, A. M. Natale, P. Bisignano, J. Suzuki, A. Fedorenko, J. Hamilton, C. Bienboire-Frosini, D. Wang, M. Marcet-Rius, D. Villanueva-Garcia, A. Gazzano, A. Dominguez-Oliva, M. Bienengraeber, K. S. Echtay, M. Klingenberg, C. Bionda, J. Portoukalian, D. Schmitt, C. Rodriguez-Lafrasse, D. Ardail, M. Bozluolcay, G. Andican, S. Firtina, G. Erkol, D. Konukoglu, R. D. Burgoyne, D. A. Butterfield, B. Halliwell, M. Cater, S. M. Holter, K. A. Chamberlain, N. Huang, Y. Xie, F. LiCausi, S. Li, Y. Li, S. L. Chan, D. Liu, G. A. Kyriazis, P. Bagsiyao, X. Ouyang, M. P. Mattson, W. Chen, J. Yang, S. Chen, H. Xiang, H. Liu, D. Lin, Z. Chen, C. Zhong, I. Cho, G. J. Hwang, J. H. Cho, H. O. Song, H. E. Ji, S. Yang, A. C. Chu, P. W. Ho, K. H. Kwok, J. W. Ho, K. H. Chan, H. F. Liu, E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, S. M. Crivelli, Z. Quadri, H. J. Vekaria, Z. Zhu, P. Tripathi, A. Elsherbini, J. Cummings, Y. Zhou, G. Lee, K. Zhong, J. Fonseca, F. Cheng, C. H. Davis, K. Y. Kim, E. A. Bushong, E. A. Mills, D. Boassa, T. Shih, S. M. de la Monte, J. R. Wands, L. E. de Vries, A. Jongejan, J. Monteiro Fortes, R. Balesar, A. J. M. Rozemuller, P. D. Moerland, G. A. Dienel, D. L. Rothman, R. Domingues, C. Pereira, M. T. Cruz, A. Silva, R. Dringen, J. M. Gutterer, J. Hirrlinger, H. H. Hoepken, T. Minich, C. Ruedig, A. Lajtha, G. E. Gibson, R. H. Du, F. F. Wu, M. Lu, X. D. Shu, J. H. Ding, G. Wu, E. Winkler, J. Fortea, J. Pegueroles, D. Alcolea, O. Belbin, O. Dols-Icardo, L. Vaque-Alcazar, P. Garcia-Nogales, K. D. Garlid, M. Jaburek, P. Jezek, D. E. Orosz, M. Modriansky, S. Vassanelli, K. N. Green, H. Khashwji, T. Estrada, F. M. LaFerla, J. Grundlingh, P. I. Dargan, M. El-Zanfaly, D. M. Wood, A. Gustavsson, N. Norton, T. Fast, L. Frolich, J. Georges, D. Holzapfel, J. N. Guzman, J. Sanchez-Padilla, D. Wokosin, J. Kondapalli, E. Ilijic, P. T. Schumacker, A. Habas, J. Hahn, X. Wang, M. Margeta, P. Hanak, K. Hayakawa, E. Esposito, Y. Terasaki, Y. Liu, C. Xing, A. Herrero-Mendez, E. Fernandez, C. Maestre, D. H. So, Z. H. Tse, H. M. Tse, D. C. Yiu, W. Y. Zhang, T. Hoang, M. Kuljanin, M. Jelokhani-Niaraki, K. A. Hogan, C. C. S. Chini, E. N. Chini, N. Hu, Y. Fu, W. F. Li, X. R. Yang, M. Cao, F. F. Li, S. G. Huang, M. O. Isei, M. Crockett, E. Chen, J. Rodwell-Bullock, T. Caroll, P. A. Girardi, M. V. Ivanova, F. R. McSorley, G. Krnac, H. T. Jacobs, D. Jiang, H. Lu, D. Jimenez-Blasco, P. Santofimia-Castano, A. Gonzalez, Y. Jing, Y. Niu, C. Liu, K. Zen, D. Li, J. M. Johnson, A. D. Peterlin, E. Balderas, E. G. Sustarsic, J. A. Maschek, M. J. Lang, S. M. Joksimovic, P. Eggan, Y. Izumi, S. L. Joksimovic, V. Tesic, R. M. Dietz, S. M. Ghodsi, J. A. Heinsbroek, J. E. Orfila, N. Busquet, B. Kaltschmidt, M. Uherek, B. Volk, P. A. Baeuerle, C. Kaltschmidt, Y. Kang, L. Chen, D. Kapogiannis, K. I. Avgerinos, B. M. Kenwood, J. L. Weaver, A. Bajwa, I. K. Poon, F. L. Byrne, B. A. Murrow, E. Klotzsch, A. Smorodchenko, L. Lofler, R. Moldzio, E. Parkinson, G. J. Schutz, N. Kyrtata, H. C. A. Emsley, O. Sparasci, L. M. Parkes, B. R. Dickie, Y. Lee, B. M. Morrison, S. Lengacher, M. H. Farah, P. N. Hoffman, S. A. Liddelow, K. A. Guttenplan, L. E. Clarke, F. C. Bennett, C. J. Bohlen, L. Schirmer, N. C. de Souza-Pinto, J. R. Slevin, R. P. Wersto, M. Zhan, J. Y. Chatton, M. Manczak, M. J. Calkins, P. H. Reddy, W. Mao, X. X. Yu, A. Zhong, W. Li, J. Brush, S. W. Sherwood, A. Montesanto, P. Crocco, M. Anfossi, N. Smirne, G. Puccio, R. Colao, S. Moriguchi, N. Shioda, Y. Yamamoto, H. Tagashira, K. Fukunaga, H. Morton, S. Kshirsagar, E. Orlov, L. E. Bunquin, N. Sawant, L. Boleng, L. Mosconi, R. D. Andrews, D. C. Matthews, T. Y. Nakamura, S. Nakao, S. Wakabayashi, K. F. Neumann, L. Rojo, L. P. Navarrete, G. Farias, P. Reyes, R. B. Maccioni, D. G. Nicholls, S. Oddo, A. Caccamo, J. D. Shepherd, M. P. Murphy, T. E. Golde, R. Kayed, D. M. A. Oliver, W. R. Pearson, L. Pellerin, A. K. Bouzier-Sore, A. Aubert, S. Serres, M. Merle, R. Costalat, H. Perreten Lambert, M. Zenger, G. Azarias, R. J. Perry, D. Zhang, X. M. Zhang, J. L. Boyer, G. I. Shulman, C. Petersen, M. D. Nielsen, E. S. Andersen, A. L. Basse, M. S. Isidor, L. K. Markussen, T. Philips, J. D. Rothstein, C. Poetschke, J. Duda, J. Benkert, E. Dragicevic, T. P. Snutch, J. Striessnig, J. A. Pradeepkiran, R. A. Rice, N. C. Berchtold, C. W. Cotman, N. Rosenberg, M. Reva, F. Binda, L. Restivo, P. Depierre, J. Puyal, J. J. Ruprecht, E. R. S. Kunji, A. S. Saab, I. D. Tzvetanova, K. A. Nave, I. D. Tzvetavona, A. Trevisiol, S. Baltan, P. Dibaj, K. Kusch, A. Serrano-Pozo, Z. Li, A. Noori, H. N. Nguyen, A. Mezlini, L. Li, M. Sheridan, B. Ogretmen, C. Simons, N. Deuter, O. Pongs, T. Schneider, A. Rupprecht, I. Sarilova, O. Ninnemann, A. U. Brauer, K. Franke, G. E. Stutzmann, I. Smith, I. Parker, R. H. Swerdlow, R. Thangavel, D. Kempuraj, S. Zaheer, S. Raikwar, M. E. Ahmed, G. P. Selvakumar, B. Vaccari-Cardoso, M. Antipina, A. G. Teschemacher, S. Kasparov, B. R. Villa, A. G. George, T. E. Shutt, P. G. Sullivan, J. M. Rho, G. C. Teskey, A. A. Willette, B. B. Bendlin, E. J. Starks, A. C. Birdsill, S. C. Johnson, B. T. Christian, S. Q. Xu, X. D. Yang, Y. W. Qian, Q. Xiao Show less
The brain’s high demand for energy necessitates tightly regulated metabolic pathways to sustain physiological activity. Glucose, the primary energy substrate, undergoes complex metabolic transformatio Show more
The brain’s high demand for energy necessitates tightly regulated metabolic pathways to sustain physiological activity. Glucose, the primary energy substrate, undergoes complex metabolic transformations, with mitochondria playing a central role in ATP production via oxidative phosphorylation. Dysregulation of this metabolic interplay is implicated in Alzheimer’s disease (AD), where compromised glucose metabolism, oxidative stress, and mitochondrial dysfunction contribute to disease progression. This review explores the intricate bioenergetic crosstalk between astrocytes and neurons, highlighting the function of mitochondrial uncoupling proteins (UCPs), particularly UCP4, as important regulators of brain metabolism and neuronal function. Predominantly expressed in the brain, UCP4 reduces the membrane potential in the inner mitochondrial membrane, thereby potentially decreasing the generation of reactive oxygen species. Furthermore, UCP4 mitigates mitochondrial calcium overload and sustains cellular ATP levels through a metabolic shift from mitochondrial respiration to glycolysis. Interestingly, the levels of the neuronal UCPs, UCP2, 4 and 5 are significantly reduced in AD brain tissue and a specific UCP4 variant has been associated to an increased risk of developing AD. Few studies modulating the expression of UCP4 in astrocytes or neurons have highlighted protective effects against neurodegeneration and aging, suggesting that pharmacological strategies aimed at activating UCPs, such as protonophoric uncouplers, hold promise for therapeutic interventions in AD and other neurodegenerative diseases. Despite significant advances, our understanding of UCPs in brain metabolism remains in its early stages, emphasizing the need for further research to unravel their biological functions in the brain and their therapeutic potential. Show less
📄 PDF DOI: 10.3389/fnins.2024.1483708
ROS amino-acid mitochondria review
Chenliang Zhang, Zhang, Chenliang, Tingting Huang +3 more · 2024 · BioMed Central · BioMed Central · added 2026-04-20
Cuproptosis is a newly identified form of cell death induced by excessive copper (Cu) accumulation within cells. Mechanistically, cuproptosis results from Cu-induced aggregation of dihydrolipoamide S- Show more
Cuproptosis is a newly identified form of cell death induced by excessive copper (Cu) accumulation within cells. Mechanistically, cuproptosis results from Cu-induced aggregation of dihydrolipoamide S-acetyltransferase, correlated with the mitochondrial tricarboxylic acid cycle and the loss of iron–sulfur cluster proteins, ultimately resulting in proteotoxic stress and triggering cell death. Recently, cuproptosis has garnered significant interest in tumor research due to its potential as a crucial therapeutic strategy against cancer. In this review, we summarized the cellular and molecular mechanisms of cuproptosis and its relationship with other types of cell death. Additionally, we reviewed the current drugs or strategies available to induce cuproptosis in tumor cells, including Cu ionophores, small compounds, and nanomedicine. Furthermore, we targeted cell metabolism and specific regulatory genes in cancer therapy to enhance tumor sensitivity to cuproptosis. Finally, we discussed the feasibility of targeting cuproptosis to overcome tumor chemotherapy and immunotherapy resistance and suggested future research directions. This study suggested that targeting cuproptosis could open new avenues for developing tumor therapy. Show less
📄 PDF DOI: 10.1186/s13045-024-01589-8
Cu Fe mitochondria review
Liping Li, Li, Liping, Houfeng Zhou +3 more · 2024 · BioMed Central · BioMed Central · added 2026-04-20
Cuproptosis, a newly identified copper (Cu)-dependent form of cell death, stands out due to its distinct mechanism that sets it apart from other known cell death pathways. The molecular underpinnings Show more
Cuproptosis, a newly identified copper (Cu)-dependent form of cell death, stands out due to its distinct mechanism that sets it apart from other known cell death pathways. The molecular underpinnings of cuproptosis involve the binding of Cu to lipoylated enzymes in the tricarboxylic acid cycle. This interaction triggers enzyme aggregation and proteotoxic stress, culminating in cell death. The specific mechanism of cuproptosis has yet to be fully elucidated. This newly recognized form of cell death has sparked numerous investigations into its role in tumorigenesis and cancer therapy. In this review, we summarized the current knowledge on Cu metabolism and its link to cancer. Furthermore, we delineated the molecular mechanisms of cuproptosis and summarized the roles of cuproptosis-related genes in cancer. Finally, we offered a comprehensive discussion of the most recent advancements in Cu ionophores and nanoparticle delivery systems that utilize cuproptosis as a cutting-edge strategy for cancer treatment. Show less
📄 PDF DOI: 10.1186/s11658-024-00608-3
Cu drug-delivery review